In a research report released Friday, FBR analyst Edward White reiterated an Outperform rating on shares of Juno Therapeutics (NASDAQ:JUNO), with a price target …
In a research report released Friday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), while slashing …
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced today that it …
Analyst Michael Schmidt from Leerink Swann shared his thoughts on Juno Therapeutics Inc (NASDAQ:JUNO), following its $10 million acquisition of RedoxTherapies. In addition to …
In a research report released today, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Juno Therapeutics (NASDAQ:JUNO), with a price target …
Juno Therapeutics Inc (NASDAQ:JUNO) is up 20% in early trading after the FDA removed the clinical hold on its Phase 2 clinical trial of …
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that the …
In a research report issued Monday, Cowen analyst Chris Shibutani reiterated an Outperform rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), while reducing the …
Analysts weighed in how the FDA clinical hold Juno Therapeutics Inc (NASDAQ:JUNO) received affects its business as well as companies with similar drugs …
